| Income Statement | 2025-06-30 | 2025-03-31 | 2024-09-30 | |
|---|---|---|---|---|
| Total revenue | 719 | 1,555 | 40 | |
| Research and development | 11,092 | 11,328 | 12,377 | |
| General and administrative | 14,900 | 10,597 | 10,265 | |
| Total operating expenses | 25,992 | 21,925 | 22,642 | |
| Loss from operations | -25,273 | -20,370 | -22,602 | |
| Other expense, net | -752 | - | -2,075 | |
| Interest income | 248 | 186 | 160 | |
| Interest expense | 264 | 900 | 783 | |
| Loss on extinguishment of debt | -1,317 | - | - | |
| Gain on other investments | 3,794 | - | - | |
| Foreign exchange gain (loss), net | 1,460 | 456 | 770 | |
| Change in fair value of digital assets, net | 1,428 | -212 | - | |
| Change in fair value of assets and liabilities, net | -7,005 | -5,497 | -1,964 | |
| Benefit from research and development tax credit | -28 | -28 | -31 | |
| Total other expense, net | -2,380 | -5,939 | -3,861 | |
| Net loss before income taxes | -27,653 | -26,309 | -26,463 | |
| Provision for income taxes | 93 | 156 | -178 | |
| Losses from investments in equity method investees, net of tax | 0 | - | -26 | |
| Net loss | -27,746 | -26,465 | -26,311 | |
| Net loss attributable to noncontrolling interests | -17 | -34 | -25 | |
| Net loss attributable to atai life sciences n.v. stockholders | -27,729 | -26,431 | -26,286 | |
| Earnings per share, basic | -0.14 | -0.15 | -0.16 | |
| Earnings per share, diluted | -0.14 | -0.15 | -0.16 | |
| Weighted average common shares outstanding attributable to atai life sciences n.v. stockholders - basic (denominator) | 196,563,699 | 176,271,176 | 160,621,817 | |
| Weighted average common shares outstanding attributable to atai life sciences n.v. stockholders - diluted | 196,563,699 | 176,271,176 | 160,621,817 | |
ATAI Life Sciences N.V. (ATAI)
ATAI Life Sciences N.V. (ATAI)